RSPH3 (NM 031924) Human Recombinant Protein – TP761392

Total Page：16

File Type：pdf, Size：1020Kb

RSPH3 (NM 031924) Human Recombinant Protein – TP761392

OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP761392 RSPH3 (NM_031924) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Purified recombinant protein of Human radial spoke 3 homolog (Chlamydomonas) (RSPH3), full length, with N-terminal GST and C-terminal HIS tag, expressed in E. coli, 50ug Species: Human Expression Host: E. coli Tag: N-GST and C-His Predicted MW: 91.5 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25mM Tris,pH8.0,150mM NaCl,10% glycerol,1% Sarkosyl. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_114130 Locus ID: 83861 UniProt ID: Q86UC2 RefSeq Size: 2201 Cytogenetics: 6q25.3 RefSeq ORF: 1680 Synonyms: CILD32; dJ111C20.1; RSHL2; RSP3 Summary: The protein encoded by this gene acts as a protein kinase A anchoring protein. Mutations in this gene cause primary ciliary dyskinesia; a disorder characterized by defects of the axoneme in motile cilia and sperm flagella. The homolog of this gene was first identified in the blue- green algae Chlamydomonas as encoding a radial spoke protein that formed a structural component of motile cilia and flagella. Alternate splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Dec 2016] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 RSPH3 (NM_031924) Human Recombinant Protein – TP761392 Product images: This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 2.

Copy Link

Recommended publications

A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
[Show full text]
Next Generation Massively Parallel Sequencing of Targeted
ARTICLE Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing Jonathan S. Berg, MD, PhD1,2, James P. Evans, MD, PhD1,2, Margaret W. Leigh, MD3, Heymut Omran, MD4, Chris Bizon, PhD5, Ketan Mane, PhD5, Michael R. Knowles, MD2, Karen E. Weck, MD1,6, and Maimoona A. Zariwala, PhD6 Purpose: Advances in genetic sequencing technology have the potential rimary ciliary dyskinesia (PCD) is an autosomal recessive to enhance testing for genes associated with genetically heterogeneous Pdisorder involving abnormalities of motile cilia, resulting in clinical syndromes, such as primary ciliary dyskinesia. The objective of a range of manifestations including situs inversus, neonatal this study was to investigate the performance characteristics of exon- respiratory distress at full-term birth, recurrent otitis media, capture technology coupled with massively parallel sequencing for chronic sinusitis, chronic bronchitis that may result in bronchi- 1–3 clinical diagnostic evaluation. Methods: We performed a pilot study of ectasis, and male infertility. The disorder is genetically het- four individuals with a variety of previously identiﬁed primary ciliary erogeneous, rendering molecular diagnosis challenging given dyskinesia mutations. We designed a custom array (NimbleGen) to that mutations in nine different genes (DNAH5, DNAH11, capture 2089 exons from 79 genes associated with primary ciliary DNAI1, DNAI2, KTU, LRRC50, RSPH9, RSPH4A, and TX- dyskinesia or ciliary function and sequenced the enriched material using NDC3) account for only approximately 1/3 of PCD cases.4 the GS FLX Titanium (Roche 454) platform. Bioinformatics analysis DNAH5 and DNAI1 account for the majority of known muta- was performed in a blinded fashion in an attempt to detect the previ- tions, and the other genes each account for a small number of ously identiﬁed mutations and validate the process.
[Show full text]
Transposon Activation Mutagenesis As a Screening Tool for Identifying
Chen et al. BMC Cancer 2013, 13:93 http://www.biomedcentral.com/1471-2407/13/93 RESEARCH ARTICLE Open Access Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics Li Chen1,2*, Lynda Stuart2, Toshiro K Ohsumi3, Shawn Burgess4, Gaurav K Varshney4, Anahita Dastur1, Mark Borowsky3, Cyril Benes1, Adam Lacy-Hulbert2 and Emmett V Schmidt2 Abstract Background: The development of resistance to chemotherapies represents a significant barrier to successful cancer treatment. Resistance mechanisms are complex, can involve diverse and often unexpected cellular processes, and can vary with both the underlying genetic lesion and the origin or type of tumor. For these reasons developing experimental strategies that could be used to understand, identify and predict mechanisms of resistance in different malignant cells would be a major advance. Methods: Here we describe a gain-of-function forward genetic approach for identifying mechanisms of resistance. This approach uses a modified piggyBac transposon to generate libraries of mutagenized cells, each containing transposon insertions that randomly activate nearby gene expression. Genes of interest are identified using next- gen high-throughput sequencing and barcode multiplexing is used to reduce experimental cost. Results: Using this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene. Analysis of co-occurring transposons integration sites in single cell clone allows for the identification of genes that might act cooperatively to produce drug resistance a level of information not accessible using RNAi or ORF expression screening approaches. Conclusion: We have developed a powerful pipeline to systematically discover drug resistance in mammalian cells in vitro.
[Show full text]
Cldn19 Clic2 Clmp Cln3
NewbornDx™ Advanced Sequencing Evaluation When time to diagnosis matters, the NewbornDx™ Advanced Sequencing Evaluation from Athena Diagnostics delivers rapid, 5- to 7-day results on a targeted 1,722-genes. A2ML1 ALAD ATM CAV1 CLDN19 CTNS DOCK7 ETFB FOXC2 GLUL HOXC13 JAK3 AAAS ALAS2 ATP1A2 CBL CLIC2 CTRC DOCK8 ETFDH FOXE1 GLYCTK HOXD13 JUP AARS2 ALDH18A1 ATP1A3 CBS CLMP CTSA DOK7 ETHE1 FOXE3 GM2A HPD KANK1 AASS ALDH1A2 ATP2B3 CC2D2A CLN3 CTSD DOLK EVC FOXF1 GMPPA HPGD K ANSL1 ABAT ALDH3A2 ATP5A1 CCDC103 CLN5 CTSK DPAGT1 EVC2 FOXG1 GMPPB HPRT1 KAT6B ABCA12 ALDH4A1 ATP5E CCDC114 CLN6 CUBN DPM1 EXOC4 FOXH1 GNA11 HPSE2 KCNA2 ABCA3 ALDH5A1 ATP6AP2 CCDC151 CLN8 CUL4B DPM2 EXOSC3 FOXI1 GNAI3 HRAS KCNB1 ABCA4 ALDH7A1 ATP6V0A2 CCDC22 CLP1 CUL7 DPM3 EXPH5 FOXL2 GNAO1 HSD17B10 KCND2 ABCB11 ALDOA ATP6V1B1 CCDC39 CLPB CXCR4 DPP6 EYA1 FOXP1 GNAS HSD17B4 KCNE1 ABCB4 ALDOB ATP7A CCDC40 CLPP CYB5R3 DPYD EZH2 FOXP2 GNE HSD3B2 KCNE2 ABCB6 ALG1 ATP8A2 CCDC65 CNNM2 CYC1 DPYS F10 FOXP3 GNMT HSD3B7 KCNH2 ABCB7 ALG11 ATP8B1 CCDC78 CNTN1 CYP11B1 DRC1 F11 FOXRED1 GNPAT HSPD1 KCNH5 ABCC2 ALG12 ATPAF2 CCDC8 CNTNAP1 CYP11B2 DSC2 F13A1 FRAS1 GNPTAB HSPG2 KCNJ10 ABCC8 ALG13 ATR CCDC88C CNTNAP2 CYP17A1 DSG1 F13B FREM1 GNPTG HUWE1 KCNJ11 ABCC9 ALG14 ATRX CCND2 COA5 CYP1B1 DSP F2 FREM2 GNS HYDIN KCNJ13 ABCD3 ALG2 AUH CCNO COG1 CYP24A1 DST F5 FRMD7 GORAB HYLS1 KCNJ2 ABCD4 ALG3 B3GALNT2 CCS COG4 CYP26C1 DSTYK F7 FTCD GP1BA IBA57 KCNJ5 ABHD5 ALG6 B3GAT3 CCT5 COG5 CYP27A1 DTNA F8 FTO GP1BB ICK KCNJ8 ACAD8 ALG8 B3GLCT CD151 COG6 CYP27B1 DUOX2 F9 FUCA1 GP6 ICOS KCNK3 ACAD9 ALG9
[Show full text]
Ciliary Dyneins and Dynein Related Ciliopathies
cells Review Ciliary Dyneins and Dynein Related Ciliopathies Dinu Antony 1,2,3, Han G. Brunner 2,3 and Miriam Schmidts 1,2,3,* 1 Center for Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg University Faculty of Medicine, Mathildenstrasse 1, 79106 Freiburg, Germany; [email protected] 2 Genome Research Division, Human Genetics Department, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 KL Nijmegen, The Netherlands; [email protected] 3 Radboud Institute for Molecular Life Sciences (RIMLS), Geert Grooteplein Zuid 10, 6525 KL Nijmegen, The Netherlands * Correspondence: [email protected]; Tel.: +49-761-44391; Fax: +49-761-44710 Abstract: Although ubiquitously present, the relevance of cilia for vertebrate development and health has long been underrated. However, the aberration or dysfunction of ciliary structures or components results in a large heterogeneous group of disorders in mammals, termed ciliopathies. The majority of human ciliopathy cases are caused by malfunction of the ciliary dynein motor activity, powering retrograde intraﬂagellar transport (enabled by the cytoplasmic dynein-2 complex) or axonemal movement (axonemal dynein complexes). Despite a partially shared evolutionary developmental path and shared ciliary localization, the cytoplasmic dynein-2 and axonemal dynein functions are markedly different: while cytoplasmic dynein-2 complex dysfunction results in an ultra-rare syndromal skeleto-renal phenotype with a high lethality, axonemal dynein dysfunction is associated with a motile cilia dysfunction disorder, primary ciliary dyskinesia (PCD) or Kartagener syndrome, causing recurrent airway infection, degenerative lung disease, laterality defects, and infertility. In this review, we provide an overview of ciliary dynein complex compositions, their functions, clinical disease hallmarks of ciliary dynein disorders, presumed underlying pathomechanisms, and novel Citation: Antony, D.; Brunner, H.G.; developments in the ﬁeld.
[Show full text]
Notch/Her12 Signalling Modulates, Motile/Immotile Cilia Ratio
RESEARCH ARTICLE Notch/Her12 signalling modulates, motile/immotile cilia ratio downstream of Foxj1a in zebrafish left-right organizer Barbara Tavares1†, Raquel Jacinto1†, Pedro Sampaio1, Sara Pestana1, Andreia Pinto2, Andreia Vaz1, Mo´ nica Roxo-Rosa1, Rui Gardner3, Telma Lopes3, Britta Schilling4, Ian Henry4, Leonor Sau´de5, Susana Santos Lopes1* 1CEDOC, Chronic Diseases Research Centre, NOVA Medical School - Faculdade de Cieˆncias Me´dicas, Universidade Nova de Lisboa, Lisboa, Portugal; 2Laborato´rio de Histologia e Patologia Comparada, Instituto de Medicina Molecular, Centro Acade´mico de Medicina de Lisboa, Lisboa, Portugal; 3Instituto Gulbenkian de Cieˆncia, Oeiras, Portugal; 4MPI of Molecular Cell Biology and Genetics, Dresden, Germany; 5Instituto de Medicina Molecular e Instituto de Histologia e Biologia do Desenvolvimento, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal Abstract Foxj1a is necessary and sufficient to specify motile cilia. Using transcriptional studies and slow-scan two-photon live imaging capable of identifying the number of motile and immotile cilia, we now established that the final number of motile cilia depends on Notch signalling (NS). We found that despite all left-right organizer (LRO) cells express foxj1a and the ciliary axonemes of these cells have dynein arms, some cilia remain immotile. We identified that this decision is taken early in development in the Kupffer’s Vesicle (KV) precursors the readout being her12 transcription. We demonstrate that overexpression of either her12 or Notch intracellular domain (NICD) *For correspondence: susana. increases the number of immotile cilia at the expense of motile cilia, and leads to an accumulation [email protected] of immotile cilia at the anterior half of the KV.
[Show full text]
The Conserved Ancestral Signaling Pathway from Cilium to Nucleus Peter Satir1,2,* and Birgit H
© 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs230441. doi:10.1242/jcs.230441 HYPOTHESIS SUBJECT COLLECTION: CILIA AND FLAGELLA The conserved ancestral signaling pathway from cilium to nucleus Peter Satir1,2,* and Birgit H. Satir1,2 ABSTRACT receptors, and for cytoplasmic molecules, including signaling Many signaling molecules are localized to both the primary cilium and proteins and signaling scaffold proteins. We seek to explain why so nucleus. Localization of specific transmembrane receptors and their many cilia-localized signaling molecules are also found in the signaling scaffold molecules in the cilium is necessary for correct nucleus. We propose here that the cilium is a dynamic storage physiological function. After a specific signaling event, signaling organelle for these molecules, some of which are specifically molecules leave the cilium, usually in the form of an endocytic vesicle targeted to the organelle upon their synthesis and concentrated in the scaffold, and move to the nucleus, where they dissociate from the cilium for effective interactions. Signaling and signaling scaffold scaffold and enter the nucleus to affect gene expression. This ancient molecules leave this storage compartment after specific stimulation pathway probably arose very early in eukaryotic evolution as the of a ciliary membrane receptor at an appropriate physiological or nucleus and cilium co-evolved. Because there are similarities in developmental time, and could then move from cilium to nucleus to molecular composition of the nuclear and ciliary pores the entry and reprogram gene expression (Fig. 1). Since entry and exit of signaling exit of proteins in both organelles rely on similar mechanisms.
[Show full text]
Novel Gene Discovery in Primary Ciliary Dyskinesia
Novel Gene Discovery in Primary Ciliary Dyskinesia Mahmoud Raafat Fassad Genetics and Genomic Medicine Programme Great Ormond Street Institute of Child Health University College London A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy University College London 1 Declaration I, Mahmoud Raafat Fassad, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Primary Ciliary Dyskinesia (PCD) is one of the ‘ciliopathies’, genetic disorders affecting either cilia structure or function. PCD is a rare recessive disease caused by defective motile cilia. Affected individuals manifest with neonatal respiratory distress, chronic wet cough, upper respiratory tract problems, progressive lung disease resulting in bronchiectasis, laterality problems including heart defects and adult infertility. Early diagnosis and management are essential for better respiratory disease prognosis. PCD is a highly genetically heterogeneous disorder with causal mutations identified in 36 genes that account for the disease in about 70% of PCD cases, suggesting that additional genes remain to be discovered. Targeted next generation sequencing was used for genetic screening of a cohort of patients with confirmed or suggestive PCD diagnosis. The use of multi-gene panel sequencing yielded a high diagnostic output (> 70%) with mutations identified in known PCD genes. Over half of these mutations were novel alleles, expanding the mutation spectrum in PCD genes. The inclusion of patients from various ethnic backgrounds revealed a striking impact of ethnicity on the composition of disease alleles uncovering a significant genetic stratification of PCD in different populations.
[Show full text]
Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
[Show full text]
Relationship Between Genotype and Laterality Defects in Primary Ciliary Dyskinesia
Relationship Between Genotype and Laterality Defects in Primary Ciliary Dyskinesia AT Barber1, AJ Shapiro2, SD Davis1, TW Ferkol3, JJ Atkinson3, SD Sagel4, SD Dell5, KN Olivier6, CE Milla7, M Rosenfeld8, L Li1, F Lin1, KM Sullivan1, M Zariwala1, MR Knowles1, MW Leigh1 1. University of North Carolina at Chapel Hill, 2. Montreal Children’s Hospital, 3. Washington University School of Medicine, 4. University of Colorado School of Medicine, 5. BC Children’s Hospital, 6. National Heart, Lung, and Blood Institute, 7. Stanford University, 8. Seattle Children’s Hospital Background Results Discussion ❖ Primary Ciliary Dyskinesia (PCD) is a rare, Laterality ❖ Individuals with mutations resulting in normal/near genetically heterogeneous disease of motile cilia Ciliary ultrastructure normal ciliary ultrastructure almost exclusively have SS SIT SA SS. The 3 individuals in this group with SIT had ❖ Common features of PCD include neonatal mutations in FOXJ1 and OFD1, both of which are respiratory distress, chronic sino-oto-pulmonary ODA (n = 242) known to be associated with laterality defects. disease, infertility, and organ laterality defects ❖ 559 total ARMC4, CCDC103, CCDC114, DNAH5, DNAI1, 96 (40%) 112 (46%) 34 (14%) DNAI2 ❖ There is a greater likelihood of a laterality defect in ❖ Normal organ arrangement (situs solitus, SS) is ❖ SS – 286 (51.2%) individuals with mutations causing ODA defects present in ~50%, mirror image organ arrangement compared to individuals with mutations causing (situs inversus totalis, SIT) is present in ~40%, and ❖ SIT – 214 (38.3%) ODA/IDA (n = 96) IDA/CA/MTD defects. other laterality defects within that spectrum (situs CFAP298, CFAP300, DNAAF1, DNAAF2, DNAAF3, 40 (42%) 43 (45%) 13 (14%) ❖ SA – 59 (10.6%) DNAAF4, DNAAF5, LRRC6, PIH1D3, SPAG1, ambiguus, SA) are present in ~10% of individuals ZMYND10 ❖ Individuals with mutations causing IDA/CA/MTD defects are known to have more severe lung ❖ Little is known about the association between ❖ Median age 11 years, range 1 month – 82 years disease.
[Show full text]
Morphology, Behavior, and the Sonic Hedgehog Pathway in Mouse Models of Down Syndrome
MORPHOLOGY, BEHAVIOR, AND THE SONIC HEDGEHOG PATHWAY IN MOUSE MODELS OF DOWN SYNDROME by Tara Dutka A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2014 © 2014 Tara Dutka All Rights Reserved Abstract Down Syndrome (DS) is caused by a triplication of human chromosome 21 (Hsa21). Ts65Dn, a mouse model of DS, contains a freely segregating extra chromosome consisting of the distal portion of mouse chromosome 16 (Mmu16), a region orthologous to part of Hsa21, and a non-Hsa21 orthologous region of mouse chromosome 17. All individuals with DS display some level of craniofacial dysmorphology, brain structural and functional changes, and cognitive impairment. Ts65Dn recapitulates these features of DS and aspects of each of these traits have been linked in Ts65Dn to a reduced response to Sonic Hedgehog (SHH) in trisomic cells. Dp(16)1Yey is a new mouse model of DS which has a direct duplication of the entire Hsa21 orthologous region of Mmu16. Dp(16)1Yey’s creators found similar behavioral deficits to those seen in Ts65Dn. We performed a quantitative investigation of the skull and brain of Dp(16)1Yey as compared to Ts65Dn and found that DS-like changes to brain and craniofacial morphology were similar in both models. Our results validate examination of the genetic basis for these phenotypes in Dp(16)1Yey mice and the genetic links for these phenotypes previously found in Ts65Dn , i.e., reduced response to SHH. Further, we hypothesized that if all trisomic cells show a reduced response to SHH, then up-regulation of the SHH pathway might ameliorate multiple phenotypes.
[Show full text]
Cardiovascular Diseases Genetic Testing Program Information
Cardiovascular Diseases Genetic Testing Program Description: Congenital Heart Disease Panels We offer comprehensive gene panels designed to • Congenital Heart Disease Panel (187 genes) diagnose the most common genetic causes of hereditary • Heterotaxy Panel (114 genes) cardiovascular diseases. Testing is available for congenital • RASopathy/Noonan Spectrum Disorders Panel heart malformation, cardiomyopathy, arrythmia, thoracic (31 genes) aortic aneurysm, pulmonary arterial hypertension, Marfan Other Panels syndrome, and RASopathy/Noonan spectrum disorders. • Pulmonary Arterial Hypertension (PAH) Panel Hereditary cardiovascular disease is caused by variants in (20 genes) many different genes, and may be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Other Indications: than condition-specific panels, we also offer single gene Panels: sequencing for any gene on the panels, targeted variant • Confirmation of genetic diagnosis in a patient with analysis, and targeted deletion/duplication analysis. a clinical diagnosis of cardiovascular disease Tests Offered: • Carrier or pre-symptomatic diagnosis identification Arrythmia Panels in individuals with a family history of cardiovascular • Comprehensive Arrhythmia Panel (81 genes) disease of unknown genetic basis • Atrial Fibrillation (A Fib) Panel (28 genes) Gene Specific Sequencing: • Atrioventricular Block (AV Block) Panel (7 genes) • Confirmation of genetic diagnosis in a patient with • Brugada Syndrome Panel (21 genes) cardiovascular disease and in whom a specific
[Show full text]